Drug Profile

CBO 421

Alternative Names: CBO-212; CBO-421; CD-421

Latest Information Update: 20 Aug 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Cidara Therapeutics
Class Antineoplastics; Drug conjugates; Immunoconjugates; Immunoglobulin Fc fragments
Mechanism of Action 5-nucleotidase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Solid tumours

Most Recent Events

31 Jul 2024 US FDA approves IND application for CBO 421 in Solid tumours
22 Apr 2024 Cidara Therapeutics plans to file an IND application for Solid tumours in mid-2024
05 Apr 2024 Pharmacodynamics data from a preclinical trial in Cancer presented at the 115^th Annual Meeting of the American Association for Cancer Research (AACR-2024)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com